Therapy News and Research

RSS

Phase III clinical trial data of Cayston versus TIS in CF patients with P. aeruginosa presented at ECFC 2010

Gilead Sciences, Inc. today announced that its head-to-head Phase III clinical trial of Cayston (aztreonam for inhalation solution) versus tobramycin inhalation solution in cystic fibrosis patients with Pseudomonas aeruginosa achieved one of its co-primary endpoints of non-inferiority for mean percent change in forced expiratory volume in one second (FEV1) percent predicted after 28 days of treatment.

19 Jun 2010

ASTRO participates in FDA's meeting to discuss highest level of safety for radiation therapy patients

The American Society for Radiation Oncology continued to advance its Target Safely initiative by participating in the Food and Drug Administration's public meeting on Device Improvements to Reduce the Number of Under-Doses, Over-Doses, and Misaligned Exposures from Therapeutic Radiation on June 9 and 10.

19 Jun 2010

E'shee Clinical Esthetic introduces revolutionary new products for skin care

E'shee Skin Care products are the result of a careful collaboration of skin care professionals, doctors and chemists; these revolutionary new products are the next step in skin care.

19 Jun 2010

Research roundup: Medical homes working in poor areas, designing insurance exchanges, health law's effects

Moving Forward On Health Reform - This edition explores the issues relating to the implementation of the Patient Protection and Affordable Care Act of 2010, including the impact of the law on health insurance as well as state and federal governments, large employers and public opinion and opportunities for small physician practices to pool resources in order support medical homes, among others (June 2010).

19 Jun 2010

LUHS opens clinic to treat debilitating effects of CPP in women

Loyola University Health System has opened a clinic to treat the debilitating effects of chronic pelvic pain in women. The clinic is located at the Loyola Outpatient Center at 2160 S. First Ave., in Maywood.

19 Jun 2010

Additional positive data from Ardea Biosciences' RDEA594 Phase 2 program presented at EULAR

Ardea Biosciences, Inc. announced that additional positive data from its Phase 2 program for RDEA594, its lead product candidate for the treatment of hyperuricemia and gout, are being presented at the Annual European Congress of Rheumatology hosted by the European League Against Rheumatism (EULAR) in Rome, Italy. RDEA594, a first-in-class selective inhibitor of the URAT1 transporter, treats the underlying cause of gout by increasing the excretion of uric acid in order to bring the body's levels of uric acid into a normal range.

18 Jun 2010

St. Jude Medical's Therapy Cool Flex Ablation Catheter granted European CE Mark approval

St. Jude Medical, Inc., a global medical device company, today announced European CE Mark approval of the Therapy™ Cool Flex™ Ablation Catheter at the 17th World Congress in Cardiac Electrophysiology and Cardiac Techniques (CardioStim). The ablation catheter is the industry's first to have a fully-irrigated and flexible tip, which can potentially improve the safety and efficacy of cardiac ablation procedures.

18 Jun 2010

Inspire's TIGER-1 Phase 3 clinical trial data with denufosol for CF presented at 33rd ECFS

Inspire Pharmaceuticals, Inc. announced today that data is being presented on denufosol tetrasodium, an investigational therapy for cystic fibrosis (CF), during an oral presentation and poster presentations at the 33rd Annual European Cystic Fibrosis Society (ECFS) Conference June 16 - 19, 2010 in Valencia, Spain.

18 Jun 2010

Women receive greater clinical benefit from CRT-Ds than men: Study

Boston Scientific Corporation today announced results from a sub-analysis of the MADIT-CRT trial data that showed women received a greater clinical benefit from its cardiac resynchronization therapy defibrillators (CRT-Ds) than men. The results were presented during the 17th Cardiostim World Congress by Jonathan Steinberg, M.D., Chief of Cardiology and Director of the Al-Sabah Arrythmia Institute, St. Luke's-Roosevelt Hospital Center, New York.

18 Jun 2010

BioSante announces presentation of LibiGel safety update at ENDO 2010

BioSante Pharmaceuticals, Inc., will present a LibiGel safety update at the 2010 Annual Meeting of the Endocrine Society (ENDO), being held from June 19-22, 2010 in San Diego, California.

18 Jun 2010

Hyperthermia in combination with particle therapy highlighted at DEGRO annual meeting

BSD Medical Corporation today announced that hyperthermia in conjunction with particle therapy was highlighted at the annual meeting of the German Society of Radiation Oncology, which was recently held in Magdeburg, Germany. A total of 2,500 scientists and radiation oncologists attended the meeting.

18 Jun 2010

90% of HCV patients to be treated with triple therapy regimens, finds Decision Resources

Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that, based on clinical profiles provided to them, surveyed clinicians estimate that one year after the launch of Vertex Pharmaceuticals/Johnson & Johnson/Mitsubishi Tanabe Pharma's telaprevir and Merck's boceprevir, at least 90 percent of hepatitis C virus patients will be treated with triple therapy regimens.

18 Jun 2010

Adult stem cell infusion during bypass surgery improves heart function: Study

Stem cell scientists from around the world gathered at the International Society of Stem Cell Research (ISSCR) in San Francisco to exchange information about the latest treatments with stem cells. An American company, TCA Cellular Therapy, LLC announced its FDA clinical trial results using adult stem cells in patients with history of a heart attack during open heart surgery.

18 Jun 2010

Serotonin transporter gene appears to increase one's risk for depression, PTSD: Study

There is a great deal of interest in factors that contribute to the vulnerability to developing post-traumatic stress disorder, or PTSD. One factor that appears to contribute to the heritable vulnerability to PTSD is a variation in the gene that codes for the serotonin transporter, also known as the serotonin uptake site. Having a shorter version of the serotonin transporter gene appears to increase one's risk for depression and PTSD after exposure to extremely stressful situations.

18 Jun 2010

Special public meeting to spotlight stem cell-based therapies for ALS

Local scientists, health advocates and leaders from the California Institute for Regenerative Medicine will gather in San Diego June 23 for a special public meeting to spotlight a new University of California, San Diego grant to pursue novel, fast-tracked stem cell-based therapies for amyotrophic lateral sclerosis, or Lou Gehrig's disease.

18 Jun 2010

Life Technologies announces product launches in concert with ISSCR 8th Annual Meeting

Life Technologies Corporation, a provider of innovative life science solutions, today announced activities and product launches in concert with the International Society for Stem Cell Research (ISSCR) 8th Annual Meeting that highlight the company's offerings of complete end-to-end solutions for stem cell research. Stem cell research has been shown to be a critical component of regenerative medicine; a basis for identifying drug targets and drug screening; and an important step in the development of therapies to treat a variety of diseases.

18 Jun 2010

New multimillion dollar BSL-3 laboratory complex at Nigerian National TB and Leprosy Training Center

This week, the U.S. Centers for Disease Control (CDC) Director, Dr. Tom Frieden, visited the Nigerian National TB and Leprosy Training Center (NTBLTC) to tour a multimillion dollar laboratory complex established by the Institute of Human Virology (IHV) of the University of Maryland School of Medicine in Baltimore, Maryland, and the Institute of Human Virology-Nigeria. This U.S.-Nigeria partnership was established in 2004 through funding from the CDC and the President's Emergency Plan For AIDS Relief (PEPFAR).

18 Jun 2010

Researchers evaluate dental pulp cells as optimal source of iPS cells

Defined sets of factors can reprogram human cells to induced pluripotent stem cells. However, many types of human cells are not easily accessible to minimally invasive procedures. In a paper published in the International and American Associations for Dental Research's Journal of Dental Research, lead researcher K. Tezuka and researchers N. Tamaoki, H. Aoki, T. Takeda-Kawaguchi, K. Iida, T. Kunisada and T. Shibata all from the Gifu University Graduate School of Medicine, Japan; and K. Takahashi, T. Tanaka and S. Yamanaka, all from Kyoto University, Japan, evaluate dental pulp cells as an optimal source of iPS cells, since they are easily obtained from extracted teeth and can be expanded under simple culture conditions.

18 Jun 2010

Researchers identify how obese people become salt sensitive, hypertensive

One way obese people become salt sensitive and hypertensive has been identified by Medical College of Georgia researchers.

18 Jun 2010

Data on BYETTA and SYMLIN injections, BYDUREON drug candidate to be presented at ADA 2010

Amylin Pharmaceuticals, Inc. today announced that the Company will present data for its FDA-approved diabetes drugs, BYETTA (exenatide) injection and SYMLIN (pramlintide acetate) injection, and its investigational diabetes drug candidate BYDUREON (exenatide extended-release for injectable suspension) at the American Diabetes Association's 70th Annual Scientific Sessions being held in Orlando, FL from June 25 to June 29.

18 Jun 2010

Therapy News and Research

Phase III clinical trial data of Cayston versus TIS in CF patients with P. aeruginosa presented at ECFC 2010

ASTRO participates in FDA's meeting to discuss highest level of safety for radiation therapy patients

E'shee Clinical Esthetic introduces revolutionary new products for skin care

Research roundup: Medical homes working in poor areas, designing insurance exchanges, health law's effects

LUHS opens clinic to treat debilitating effects of CPP in women

Additional positive data from Ardea Biosciences' RDEA594 Phase 2 program presented at EULAR

St. Jude Medical's Therapy Cool Flex Ablation Catheter granted European CE Mark approval

Inspire's TIGER-1 Phase 3 clinical trial data with denufosol for CF presented at 33rd ECFS

Women receive greater clinical benefit from CRT-Ds than men: Study

BioSante announces presentation of LibiGel safety update at ENDO 2010

Hyperthermia in combination with particle therapy highlighted at DEGRO annual meeting

90% of HCV patients to be treated with triple therapy regimens, finds Decision Resources

Adult stem cell infusion during bypass surgery improves heart function: Study

Serotonin transporter gene appears to increase one's risk for depression, PTSD: Study

Special public meeting to spotlight stem cell-based therapies for ALS

Life Technologies announces product launches in concert with ISSCR 8th Annual Meeting

New multimillion dollar BSL-3 laboratory complex at Nigerian National TB and Leprosy Training Center

Researchers evaluate dental pulp cells as optimal source of iPS cells

Researchers identify how obese people become salt sensitive, hypertensive

Data on BYETTA and SYMLIN injections, BYDUREON drug candidate to be presented at ADA 2010

Advancing Neuroscience Research Through Collaboration and Patient-Centered Innovation

The impact of vibration on microscopy

How Omics Technologies Are Transforming Biological Research and Drug Discovery

Latest News